All In MedTech

Device Trial Radar · NCT03214627

Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

ANEMEX UK Trial: Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

Last checked: Nov 20, 2026Latest source record: Jan 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

88

Actual

Start

Dec 10, 2018

Primary completion

May 21, 2019

Study completion May 21, 2019

Sponsor

Lead sponsor
Vifor Fresenius Medical Care Renal PharmaNot on our public-company list
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials; Fresenius Medical Care Deutschland GmbH
First posted
Jul 11, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 19 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Fresenius Medical Care has developed a computer software programme called the Anaemia Control Management (ACM) software to assist in the anaemia management of patients with chronic kidney disease (CKD) undergoing hemodialysis. This trial is designed to assess the effectiveness of this ACM software on anaemia management in routine clinical practice. However, all ultimate decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the discretion of the Investigator. The trial consists of a retrospective (historical) control period and a prospective (going forward) period. During the prospective period, the ACM will be used to assist the Investigators' decision making and will help the Investigators to administer a personalised intravenous (IV) iron and red blood cell stimulating agent (ESA) therapy, whereas treatment according to standard of care will be documented retrospectively for the same patients during the retrospective period of the trial. Thus, patients can serve as their own control.

Conditions

  • Anemia
  • End Stage Renal Disease

Interventions

  • Anemia Control Model (ACM)Device

    The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.

  • IV ironDrug

    IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator

  • Erythropoiesis-Stimulating Agent (ESA)Drug

    ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the proportion of patients with haemoglobin within the target range as compared to the historical control period (non-inferiority testing)Time frame: Month -6 to Month -1 compared with Month +1 to Month +6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kings College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.